Lincoff, A Michael <br/><br/>
Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.  [electronic resource] 

 -  American heart journal  Sep 2013 
 - 429-34 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1097-6744 
<br/><br/><label>Standard No.: </label>10.1016/j.ahj.2013.05.013  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acute Coronary Syndrome--complications<br/>Diabetes Mellitus, Type 2--complications<br/>Double-Blind Method<br/>Female<br/>Hospitalization--statistics & numerical data<br/>Humans<br/>Male<br/>Middle Aged<br/>Morbidity<br/>Myocardial Infarction--mortality<br/>Oxazoles--therapeutic use<br/>Peroxisome Proliferator-Activated Receptors--agonists<br/>Risk Factors<br/>Stroke--mortality<br/>Thiophenes--therapeutic use<br/>Treatment Outcome